A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson\'s Disease. Primary objective of the study is to evaluate the safety and tolerability of MT101-5 400 mg and 600 mg oral tablet total daily dose compared to Placebo in subjects with Parkinson\'s Disease.
Epistemonikos ID: b631cfe31816bf62f4b9b346372a0c01b32e424f
First added on: May 15, 2024